Latest

02.13.2024

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for Treatment of Severe Acute Kidney Injury

Read Article
01.22.2024

CalciMedica Announces Private Placement of up to Approximately $55 Million

Read Article
06.05.2023

Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Car

Read Article
05.18.2023

OncoResponse Awarded $13 Million in Funding from CPRIT to Advance Cancer Immunotherapy

Read Article
01.17.2023

Leap Therapeutics Acquires Flame Biosciences

Read Article
01.09.2023

Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma

Read Article
11.21.2022

Graybug and CalciMedica Enter into Definitive Merger Agreement

Read Article
08.31.2022

Scientific Inquirer: Industry Matters: From Elite Responders to M2 macrophages – OncoResponse’s approach to cancer immunotherapy

Read Article
Up NextAbout Us